Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
Healthcare
$1.40 +3.16%
+$0.05 today
- Market cap
- $60.08M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
52W Low $1.15High $3.56
Volume 0.37M
Average 0.60M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$84.11M
FY 2025 · Annual
Net Income
-$77.91M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 536K | 1.01M | 1.36M |
| Gross Profit | 0 | 0 | (536K) | (1.01M) | (1.36M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.72M | 23.95M | 45.49M | 63.99M | 59.99M |
| Selling, General & Admin | 2.47M | 8.71M | 21.21M | 25.21M | 24.12M |
| Operating Expenses | 16.18M | 32.66M | 66.7M | 88.19M | 82.76M |
| Depreciation & Amortization | 37K | 364K | 536K | 1.01M | 1.36M |
| EBITDA | (16.21M) | (30.8M) | (59.85M) | (79.55M) | (76.55M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (16.18M) | (32.66M) | (67.24M) | (89.2M) | (84.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 7.04M | 9.2M | 6.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (59K) | 1.49M | 6.85M | 8.64M | 6.21M |
| Income Before Tax | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.26) | (1.42) | (2.74) | (2.10) | (2.02) |
| EPS (Diluted) | (1.26) | (1.42) | (2.74) | (2.10) | (2.02) |
| 12.91M | 21.92M | 22.08M | 38.3M | 38.51M | |
| 12.91M | 21.92M | 22.08M | 38.3M | 38.51M |
ACRV Earnings Waterfall · TTM
NASDAQ:ACRV · Revenue to Net Income
Key Ratios
EPS$-2.00
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-0.9
P/S Ratio0.0
Analysis
$0 of revenue converted into -$77.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.00, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 |
How much revenue does ACRV generate?
Acrivon Therapeutics, Inc. Common Stock (ACRV) reported $0.00 of revenue in fiscal 2025.
Is ACRV profitable?
Acrivon Therapeutics, Inc. Common Stock (ACRV) reported -$77.91M of net income.
Continue the stock analysis
Jump to another research area for this company.